At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Trebananibbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
In Brief
A Phase 2 clinical trial evaluating Trebananib for Endometrial Adenocarcinoma and 6 related conditions. Completed, enrolled 35 participants across 33 sites.
Detailed Summary
This phase II trial studies the side effects and how well trebananib works in treating patients with persistent or recurrent endometrial cancer. Trebananib may stop the growth of endometrial cancer by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Endometrioid Stromal Sarcoma, Recurrent Uterine Corpus Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartJun 2011
Primary CompletionJul 2016
TodayJul 2026
First PostedSep 28, 2010
Enrollment StartJun 6, 2011
Primary CompletionJul 16, 2016
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 15.8 years ago
Interventions
Trebananibbiological
Given IV